Table 2.
Baseline characteristics of patients enrolled in each arm of trials comparing effect of CETPi to placebo
| Arm (n) | Mean Age (SD) | Male sex (%) | Diabetes (%) | Mean BMI (SD) | Statin use (%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study | Drug | CETPi | Placebo | CETPi | Placebo | CETPi | Placebo | CETPi | Placebo | CETPi | Placebo | CETPi | Placebo |
| ILLUMINATE9 | Torcetrapib | 7533 | 7534 | 61.3±7.6 | 61.3±7.6 | 77.7 | 77.8 | 43.5 | 45.2 | 30.1±5.7 | 30.2±5.6 | 100 | 100 |
| Dal-OUTCOMES12 | Dalcetrapib | 7938 | 7933 | 60.3±9.1 | 60.1±9.1 | 80 | 81 | 24 | 25 | 28.6±5.0 | 28.6±5.1 | 97 | 98 |
| ACCELERATE10 | Evacetrapib | 6038 | 6054 | 64.8±9.4 | 65.0+9.5 | 77 | 77 | 68.4 | 67.9 | NR | NR | 96.4 | 96.6 |
| REVEAL8 | Anacetrapib | 15225 | 15224 | 67±8 | 67±8 | 83.9 | 83.8 | 37.1 | 37.2 | 28.6±5.0 | 28.6±5.1 | 97.2 | 96.9 |
| DEFINE11 | Anacetrapib | 811 | 812 | 62.5±8.7 | 62.9±9.0 | 77.6 | 76.1 | 53 | 53.2 | 30.4±5.5 | 30.1±5.2 | 99.5 | 99.1 |
BMI, body mass index; CETPi, CETP inhibitor.